AZRA FAROOQUI: Open Payments
NPI 1366621351 · SPRINGFIELD, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 43 payments from 10 companies in 2025. Trend: 2023 $523 · 2024 $660 · 2025 $872
Food & beverage: $765Education: $107
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $230 |
| Otsuka America Pharmaceutical, Inc. | 14 | $158 |
| Alkermes, Inc. | 6 | $106 |
| Vanda Pharmaceuticals Inc. | 3 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
| Neurocrine BioSciences, Inc. | 2 | $44 |
| ABBVIE INC. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
Products named: UZEDY, FANAPT, ARISTADA, CAPLYTA, REXULTI, ABILIFY ASIMTUFII, INVEGA SUSTENNA, INGREZZA.
Industry payments across VA — which companies pay providers there.
